PTH receptor agonists
- Intermittent PTH signaling builds bone
- Teriparatide/abaloparatide: very high fracture risk
- Palopegteriparatide replaces PTH in hypopara
- Osteoporosis courses are time-limited
- Follow anabolic therapy with antiresorptive
- Hypercalcemia can occur
- Use differs dramatically by indication
Class at a glance
- Intermittent PTH signaling builds bone
Practical pearls
- Palopegteriparatide replaces PTH in hypopara
Clinical role
- Follow anabolic therapy with antiresorptive
- Use differs dramatically by indication
Safety / monitoring
- Teriparatide/abaloparatide: very high fracture risk
- Osteoporosis courses are time-limited
- Hypercalcemia can occur
Drugs in this class (2)
All drug classes · Open the interactive console ↗
